Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020

News | Cath Lab

Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI

November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to ...

November 16, 2020

The AHA 2020 late-breaking SAMSON Trial found side effects reported from statins are real, but appear due to the psychological rather than the pharmacological effects of the cholesterol lowering drugs. #AHA20 #AHA2020

News | Pharmaceuticals

Side Effects Attributed to Statins Same for Those Taking a Placebo

November 16, 2020 — Among patients who stopped taking their cholesterol-lowering statin medication due to side effects ...

November 16, 2020

News | Pharmaceuticals

New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender

November 16, 2020 — Novartis announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11 ...

November 16, 2020

NIH trial, the Outcomes Related to COVID-19 treated with Hydroxychloroquine among Inpatients with symptomatic Disease (ORCHID), showed no difference in deaths between placebo and hydroxychloroquine. Getty Images

News | Coronavirus (COVID-19) | Dave Fornell, Editor

Hydroxychloroquine Does Not Help Hospitalized COVID-19 Patients

November 9, 2020 — A National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of hydro ...

November 09, 2020

hort-term hydroxychloroquine treatment is not associated with lethal heart rhythms in patients with COVID-19 (SARS-CoV-2) who are risk assessed prior to receiving the drug. That is the finding of research published today in EP Europace, a journal of the European Society of Cardiology (ESC). #COVID19 #SARSCoV2 #hydroxychloroquine

News | Coronavirus (COVID-19)

Short-term Hydroxychloroquine Use in COVID-19 Patients Does Not Cause Lethal Arrhythmias if Screened

September 25, 2020 — Short-term hydroxychloroquine treatment is not associated with lethal heart rhythms in patients ...

September 25, 2020

SARS-CoV-2 infection of cells shown in green, left. This is inhibited by a modified form of cholesterol called 25-hydroxycholesterol (25HC), as seen in the cells in the right image. 25HC activates an enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. It is a normally occurring process that gets kicked into high gear during some viral infections. Image from UC San Diego Health Sciences.

News | Coronavirus (COVID-19)

Statins May Reduce COVID-19 Severity

September 24, 2020 — Analyzing anonymized patient medical records, University of California (UC) San Diego Health resear ...

September 24, 2020

News | Coronavirus (COVID-19)

COVID-19 Therapy Drug Azithromycin May Increase Risk for Cardiac Events

September 17, 2020 — Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact of C ...

September 17, 2020

The NIH is heading three studies looking at various blood thinners and anticoagulants to treat COVID-19 patients with VTE.

News | Coronavirus (COVID-19)

NIH Trials Evaluate Various Blood Thinners to Treat COVID-19

September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials ...

September 11, 2020

Videos | Pharmaceuticals

VIDEO: Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

Matthew Budoff, M.D., director of cardiovascular CT at The Lundquist Institute, and professor of medicine at the David ...

September 10, 2020

Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months in the EVAPORATE Trial

News | Pharmaceuticals

Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

September 10, 2020 - Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque ...

September 10, 2020

News | Coronavirus (COVID-19)

First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients

September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin ...

September 08, 2020

Dapagliflozin (Farxiga) heart failure drug performs very will to improve outcomes for patients with chronic kidney disease.

News | Pharmaceuticals

Dapagliflozin Meets All Endpoints to Treat Chronic Kidney Disease

July 28, 2020 — AstraZeneca's heart failure medication dapagliflozin (Farxiga) significantly reduced the worsening of ...

July 28, 2020

The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. FDA says hydroxychloroquine does not work to treat COVID-19.Getty Images #COVID19 #COVID19update #SARSCoV2

Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine for COVID-19

June 15, 2020 — The U.S. Food and Drug Administration (FDA) today revoked the emergency use authorization (EUA) that ...

June 15, 2020

Videos | Coronavirus (COVID-19)

VIDEO: Why QT-prolongation Occurs in COVID-19 Patients on Hydroxychloroquine and Azithromycin

Interview with Andrew D. Krahn, M.D.,FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of ...

May 28, 2020

Feature | Coronavirus (COVID-19)

WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19

May 27, 2020 — Two of the front-line drugs being used to treat COVID-19 (SARS-CoV-2) patients are hydroxychloroquine and ...

May 27, 2020